These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 10673995)

  • 1. A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma.
    Sulkowski U; Büchler M; Pederzoli P; Arnold R; Dinse P; Kay A; Haus U; Beger HG
    Eur J Cancer; 1999 Dec; 35(13):1805-8. PubMed ID: 10673995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer.
    Friess H; Büchler M; Beglinger C; Weber A; Kunz J; Fritsch K; Dennler HJ; Beger HG
    Pancreas; 1993 Sep; 8(5):540-5. PubMed ID: 8302789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
    Wenger FA; Jacobi CA; Siderow A; Zieren J; Zieren HU; Müller JM
    Chirurg; 1999 Jun; 70(6):694-9. PubMed ID: 10427457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
    Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ
    Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of a distal bile duct carcinoma after treatment with octreotide for 6 months.
    Sulkowski U; Dinse P; Haus U; Collins W
    Digestion; 1997; 58(4):407-9. PubMed ID: 9324171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas.
    Rosenberg L; Barkun AN; Denis MH; Pollak M
    Cancer; 1995 Jan; 75(1):23-8. PubMed ID: 7804972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
    Wenger FA; Zieren HU; Jacobi CA; Müller JM
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1348-50. PubMed ID: 9931878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
    Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II pilot trial of 13-cis retinoic acid and interferon-alpha in patients with advanced pancreatic carcinoma.
    Brembeck FH; Schoppmeyer K; Leupold U; Gornistu C; Keim V; Mössner J; Riecken EO; Rosewicz S
    Cancer; 1998 Dec; 83(11):2317-23. PubMed ID: 9840531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature.
    Fazeny B; Baur M; Prohaska M; Hudec M; Kremnitzer M; Meryn S; Huber H; Grunt T; Tuchmann A; Dittrich C
    J Cancer Res Clin Oncol; 1997; 123(1):45-52. PubMed ID: 8996540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term octreotide treatment induces apoptosis in human pancreatic cancer xenografts.
    Zalatnai A; Bocsi J
    In Vivo; 2006; 20(4):549-52. PubMed ID: 16900788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Insulinoma effectively controlled with low dose of octreotide acetate].
    Fukuoka K; Matsushita M; Murase T; Yamamori I
    Nihon Naika Gakkai Zasshi; 2007 Dec; 96(12):2786-8. PubMed ID: 18203414
    [No Abstract]   [Full Text] [Related]  

  • 13. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.
    Lau SC; Abdel-Rahman O; Cheung WY
    Med Oncol; 2018 Aug; 35(9):123. PubMed ID: 30078166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma.
    Ingle JN; Suman VJ; Kardinal CG; Krook JE; Mailliard JA; Veeder MH; Loprinzi CL; Dalton RJ; Hartmann LC; Conover CA; Pollak MN
    Cancer; 1999 Mar; 85(6):1284-92. PubMed ID: 10189133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
    Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.
    Helle SI; Geisler J; Poulsen JP; Hestdal K; Meadows K; Collins W; Tveit KM; Holly JM; Lønning PE
    Br J Cancer; 1998 Jul; 78(1):14-20. PubMed ID: 9662244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin analogs and prednisone in advanced refractory thymic tumors.
    Palmieri G; Montella L; Martignetti A; Muto P; Di Vizio D; De Chiara A; Lastoria S
    Cancer; 2002 Mar; 94(5):1414-20. PubMed ID: 11920496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
    J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of octreotide in the treatment of pancreatic cancer.
    Ebert M; Friess H; Beger HG; Büchler MW
    Digestion; 1994; 55 Suppl 1():48-51. PubMed ID: 8132137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
    Katopodis O; Polyzos A; Kentepozidis N; Giassas S; Rovithi M; Bozionelou V; Kalbakis K; Vamvakas L; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):361-8. PubMed ID: 20428874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.